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Introduction
About the Conference
The workshop highlighted emerging diagnostic technologies that had been presented at the site
and assembled and/or tested by the attendees during the hands-on sessions. The venue at-
tracted more than 30 presenters and 126 participants (39 international and 87 African). Specifi-
cally, African participants were from Kenya (73), Uganda (7), Tanzania (3), Ethiopia (1),
Rwanda (1), Zimbabwe (1), and South Africa (1). African participants were affiliated with uni-
versities (41 from Nairobi, Kenyatta, Makerere, Egerton, Aga Khan, Strathmore, and others),
hospitals and ministries, (5) or research institutes (38) such as the Institute of Primate Research
(IPR), The Kenya Medical Research Institute (KEMRI), the International Livestock Research
Institute (ILRI), The International Centre of Insect Physiology and Ecology (ICIPE), and the
Tsetse & Trypanosomiasis Research Institute (TTRI/EGFAR). More detailed summary of the
participants can be found on page 75 of the conference program (provided as a supplementary
file). The workshop program consisted of three days of presentations, including a poster ses-
sion and an additional two full days of hands-on demonstrations of devices that have a poten-
tial to become next generation diagnostic platforms. Reports on the development of many of
these devices have been published, and their descriptions can be found in references [1–17]
and Table 1. Importantly, however, the majority of the technologies presented had not been
tested outside of a research laboratory setting. Out of 18 point-of-care (POC) devices brought
to the site, 12 were assembled on-site, and 4 were manufactured from raw components
(Table 1) in a self-made production facility, which was set up in a laboratory at the IPR (http://
www.primateresearch.org/). A full description of the devices, list of conference presenters, at-
tendees, and abstracts can be found in the conference program (provided as a supplementary
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003676 May 14, 2015 1 / 16
OPEN ACCESS
Citation: Derda R, Gitaka J, Klapperich CM, Mace
CR, Kumar AA, Lieberman M, et al. (2015) Enabling
the Development and Deployment of Next Generation
Point-of-Care Diagnostics. PLoS Negl Trop Dis 9(5):
e0003676. doi:10.1371/journal.pntd.0003676
Editor: Patrick J. Lammie, Centers for Disease
Control and Prevention, UNITED STATES
Published: May 14, 2015
Copyright: © 2015 Derda et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Funding: The workshop described in this publication
was made possible by the financial support from the
following organizations: Grand Challenges Canada
("Rising Star" Award to RD), Alberta Glycomics
Centre, University of Alberta Faculty of Science,
SENTINEL Bioactive Paper Network, and German
Federal Ministry for Economic Cooperation and
Development (BMZ). The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript
Competing Interests: The authors have declared
that no competing interests exist.
file S1 Text); additional information, such as the videos of demonstrations and talks can be
found at: http://www.glycomicscentre.ca/conferences/past-workshops/ and https://www.
youtube.com/watch?v = cYTs3FoOOo4.
Genesis of This Document
During the conference, it became clear that ideas generated via interactions between North
American, South American, European, and African participants could be instructive for the
wider community of scientists working on POC diagnostics and the diseases that dispropor-
tionately affect low- and middle-income countries. At the crux of this document is our belief
that change is only possible by building partnerships with the health science and health care
systems in these countries. The demand for low cost, POC diagnostics exists, but the commer-
cialization mechanisms needed to see them through to distribution and sustainability are, for
the most part, inefficient or nonexistent. Only by building and reinforcing these systems will
POC diagnostics find their way into the hands of the health care providers or clinicians who
need solutions. This document shares ideas that we developed during in-person discussions
and continuing correspondence between the authors from the 2012 workshop until 2015. We
focus on applications in East Africa; however, we anticipate that many of these recommenda-
tions can be applied generally. We suggest solutions to the most commonly identified “broken”
links along the value chain that connects ideas in the research lab with doctors, health care
workers, and patients in the clinic. We anticipate that this document will serve as a renewed
call to action for the development and successful deployment of POC diagnostics in low
Table 1. Devices demonstrated at the workshop.
Device Lab/Group (University) Target/Capability Assembled On-
Site
References
Webcam microscope Hackteria Digital microscopy Y [18]
DIY laser cutter Hackteria Fabrication Y [19]
Paper-based device Diagnostics for all Liver function [16,20,21]
Aqueous multiphase systems & egg
beater centrifuge
Whitesides (Harvard) Hematology Y [1,13,22–
24]
Paper milliﬂuidic test card Lieberman (Notre Dame) Detection of fake
pharmaceuticals
Y [17]
2DPN for controlled ﬂow Yager (U. Washington) ELISA Y [5,7]
Microﬂuidic hematology analyzer Morgan (U. Southampton) Complete blood count Y [8,25]
3D paper devices Martinez (Cal Poly) Urinanalysis Y* [12]
Polymer-based color tunable materials Serpe (U. Alberta) Glucose Y [26]
Cell sorting with pegs Tegenfeldt (Lund University) Parasite detection Y [9]
BacChip Weibel (U. Wisconsin) Bacterial infections [10,27]
DNA ampliﬁcation by destabilization Gibbs-Davis (U. Alberta) Nucleic acid detection Y [14,28]
Portable bacteria cultures Derda (U. Alberta) Environmental monitoring Y* [11]
Adherio Klapperich/Gomez-Marquez (Boston
University/MIT)
TB Drug Adherence
monitoring
Y
Shrink-wrap microﬂuidics Khine (UC Irvine) Fabrication of microﬂuidics Y* [4]
Electrophoretic focusing chip Cooper (U. Glasgow) Trypanosomiasis [29]
Plasma separation on chip Shu (Heriot-Watt) Sample preparation
Multiwell plates Carrilho (U. Sao Paulo) Multiwell analysis Y* [2]
(*Devices were produced on site)
doi:10.1371/journal.pntd.0003676.t001
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resource settings, and we address these comments to funders, governments, researchers, clini-
cians, and, most importantly, policy makers.
The Continuing Need for POC Diagnostics in Low Resource Settings
As the developing world strives to meet the Millennium Development Goals (MDGs) and im-
prove quality of life [30], it will be critical to address the current heavy burden of diseases. In
the therapeutic process, correct and timely diagnosis is the pillar on which treatment, follow-
up, and public control measures hinge. Examples of success exist. The introduction of rapid
tests for HIV has contributed greatly to widespread testing, demand for downstream services,
prompt diagnosis, treatment, follow-up, and behavior change [31,32].
An example of partial success is the development and commercialization of rapid diagnostic
tests (RDTs) for malaria. Malaria RDTs have been a critical tool for health care workers operat-
ing in remote locations lacking access to electricity, experienced microscopists, or other re-
sources required to diagnose and treat patients with confidence [33]. These tests have been
used to manage febrile (i.e., symptomatic) children in countries with endemic malaria [34]. De-
spite this success, outstanding challenges still exist in malaria diagnostics. Although the sensi-
tivity of existing RDTs are generally able to detect malaria in a febrile patient—an important
step in effective programs to manage the disease—the sensitivity is not always sufficient to de-
tect lower levels of infections and asymptomatic carriers, which are both important in eradica-
tion campaigns [35,36]. Many malaria RDTs do not detect mixed infections and, depending on
the antigenic marker used, may not be effective in monitoring responses to therapy [37,38]. A
further obstacle to adoption is the attitude of health care workers towards the use of these tests
[39]. Recent work in Senegal provides a model of training and implementation that may be
able to overcome some of these challenges [40]. Additionally, the World Health Organization
(WHO), in collaboration with the Foundation for Innovative New Diagnostics (FIND) and
others, has undertaken a rigorous evaluation of the multitude of RDTs on the market; this as-
sessment will provide users with the information required to choose the best tests available for
their needs [41].
In addition to improving existing RDTs, new tests must be developed to provide options to
assist in the monitoring and control of emerging diseases or those considered difficult to diag-
nose at the POC. Tuberculosis is an excellent example of this category of disease. One third of
the world population is infected with tuberculosis (TB), approximately 9 million persons are
infected each year, and there are approximately 1.2 million deaths annually [42]. Diagnostics
for TB, such as Cepheid’s GeneXpert, are an excellent display of advances in diagnostic tech-
nologies but are still too expensive and bulky for POC use [43]. The 2014–2015 Ebola outbreak
in West Africa and the subsequent challenges in diagnosing and controlling the disease is a
classical gap that could be bridged by POC diagnostics. Timely and reliable diagnosis of cases
in primary health care facilities might have altered the course of the outbreak, saving many
lives with minimal disruption of the day-to-day life in the affected areas (Dhillon, 2014 #172).
These POC diagnostics would not only diagnose Ebola but in a multiplex design be able to rule
out other febrile infections prevalent in the region. Other priority areas include neglected tropi-
cal diseases that afflict over 1,000,000,000 of the world’s poor [44], and non-HIV sexually
transmitted infections (e.g., gonorrhea, chlamydia, and syphilis). Additionally, the rising bur-
den of noncommunicable diseases in low- and middle-income countries (e.g., hypertension, di-
abetes, and cancer [45]) amplifies the need for simple tests that can diagnose the disease and its
complications, track treatment progress milestones, and monitor serum drug levels. As the de-
mographics of disease change, future tests will play a greater role in preventive medicine rather
than curative medicine. As efforts accelerate towards eliminating diseases, including malaria,
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simple tests will be critical in monitoring epidemiological trends in communities (e.g., gameto-
cytemia prevalence) [35]. All disease control efforts require effective and reliable diagnostics in
order to carry out interventions that can ultimately succeed.
Definitions
To properly frame the problems and proposed solutions (Table 2), we define key
concepts below.
Point-of-care diagnostics. We define POC diagnostics as small, portable devices capable
of detecting the presence or absence of a disease-causing agent, a disease, or quantifying the se-
verity or a change in severity of a disease. A broader subset of POC tests also includes portable
tests for quality control; for example, prototypes of the devices for detection of counterfeit
pharmaceuticals were displayed and tested at this conference [17]. WHO and others [46] have
outlined the functional and performance specifications for “ideal” POC diagnostic assays [47];
we will not reiterate those lists here. We do include in our definition stand-alone, one-time use
devices that require no additional instrumentation, minimally-instrumented devices, and de-
vices that include portable and easy-to-use instrumentation (e.g., cell phone-based approaches
to telemedicine [48,49]).
Value chain. Over the course of the workshop, it became clear that scientists involved in
developing or using assays felt confident in their ability to define and tackle technical problems
in device and assay design. However, we felt less confident as a group in our ability to identify
Table 2. Barriers and potential solutions to advancing POC diagnostics research.
Current Barriers Potential Solutions
•Disconnect between developers and end users •Begin collaborations early (i.e., needs and design
process)
•Publish in open-access journals to make information
available to both users and developers
•Lack of funding for international collaboration •Advocate for multidisciplinary research funding
•Engage in policy discussions and set priorities
•Establish funds for exchange programs
•Funding priorities do not always reﬂect local
priorities in developing countries
•Direct partnerships and assessments
•Create new metrics to demonstrate impact of POC
diagnostics on health costs & quality
•Costs of intellectual property (IP) •Establish protocols for transferring technology between
countries
•Resistance to interdisciplinary work in some
countries
•Collaboration and modeling interdisciplinary work
•Distrust of Western researchers •High quality control standards
•Equal partnerships (local co-PI)
•Inertia to continue existing practices •Develop and update health curricula to reﬂect
advances in POC diagnostics
•Refresher courses to update users on new devices
•Engage with mass media to disseminate advances
•Dedicate online resources to aid in the use and
interpretation of POC diagnostics
•Failure of prototypes to become products •Design with sustainability in mind
•Understand supply chains
•Use proper controls
•User-centered design
doi:10.1371/journal.pntd.0003676.t002
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problems along the entire chain of events between the design and development of a new device
and its adoption by an end user. It is useful to define this entire process as the POC diagnostic
“value chain” (Fig 1). Each link in this chain represents a potential point of failure for the entire
progression from research and development to the deployment of a product that becomes part
of patient care [50,51]. This chain includes: (i) assessments of clinical, market, and end user
needs; (ii) determination of demand for the product (in part) through marketing, procurement,
and partnership with local governmental and nongovernmental organizations; (iii) design and
development of diagnostic assays and related devices; (iv) evaluation of product deliverability
through considerations of packaging, shipping (and/or importing), storage, last mile distribu-
tion, and inventory control; (v) establishment of quality assurance and quality control process-
es for scaled-up manufacture of POC tests; (vi) filing for regulatory approval for the intended
use of the technology in a broadly global marketplace; (vii) on-the-ground efforts towards en-
suring adoption of the technology by users, clinics, and research laboratories; and (viii) organi-
zation of postdelivery support through user training, technical assistance, and maintenance of
equipment. Ideally, this chain incorporates end user testing, feedback on performance to the
developers, and subsequent cycles of POC test optimization and field testing.
Barriers to the Successful Development and Distribution of POC
Diagnostics in Low Resource Settings
It is common to discuss the “valley of death” analogy as the gap in development between the
proof-of-concept demonstration of a new device and its eventual debut in the marketplace.
Kumar et al. provide strategies for transitioning from a proof-of-concept to testing in field set-
tings [52], while Chin et al. discuss different cases of commercialization [53]. These, and other
reviews on POC diagnostics [54,55], make it clear that there are numerous barriers to the suc-
cessful implementation of POC diagnostics in resource-limited settings, which can be
Fig 1. Value chain of point-of-care diagnostics. The top part displays the stakeholders that are involved in
the development, commercialization, roll out, and integration of point-of-care diagnostic tests into control and
surveillance programs
doi:10.1371/journal.pntd.0003676.g001
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associated with a particular step along the value chain. Some of the barriers related to interna-
tional collaborations and technology for global health are discussed below.
Collaboration between Laboratories across Continents
Workshop attendees universally expressed a desire to set up strong transcontinental collabora-
tions. However, the participants found that transcontinental collaborations can be challenging
to establish and maintain due to limited federal funding (e.g., the United States Agency for In-
ternational Development [USAID]) and other support structures (e.g., the Bill and Melinda
Gates Foundation and Grand Challenges Canada) for these kinds of activities. Although suc-
cessful programs (e.g., the Center for Global Health at Massachusetts General Hospital) and or-
ganizations (e.g., PATH and Seeding Labs) exist, extensive institutional mechanisms to enable,
foster, and support the growth of these partnerships are needed for change to be possible.
While the main goal of most collaborations is to accelerate translation of technologies, attend-
ees felt that developers of technology are often disconnected from the actual needs of the popu-
lations they aim to serve. We reached a consensus that these misunderstandings of need are
not born from misinformation but rather a lack of information. This gap arises from poor or
nonexistent communication among stakeholders in governments, in clinics, and in research
laboratories. Failings in communication are not unidirectional; researchers and scientists often
do not know the working environment of health care workers in low-resource settings, and,
conversely, health care workers in low-resource settings are often not aware of beneficial tech-
nological advances. An outcome of this workshop was the understanding that developers
should engage end users before tests are designed and research and development (R&D) be-
gins. A challenge with early engagement is obtaining resources to support travel between the
developers and end users.
Critical Gaps in Needs Assessment
Often, there is a lag in time between the actual needs “on the ground” and the recognition of
those needs by the global development and research communities. For example, funding mech-
anisms and calls for proposals in research areas specific to POC diagnostics represent needs at
a particular point in time. These areas may be considered the “gold standard” by technology
developers even as new challenges and opportunities arise. Although this model has been suc-
cessfully used to coordinate global efforts, such mechanisms may miss opportunities where
new technologies could have an impact. There is a well-recognized shortage of investment in
areas of R&D that addresses specific health problems of developing economies [56]. For exam-
ple, North American and European researchers may consider Rift Valley Fever and plant virus-
es to be “niche” applications in diagnostics, and yet a strong need exists for diagnostic solutions
for these diseases.
Global research priorities are still driven by the “Big Three” (HIV, TB, and malaria), even
though a global epidemiological transition has occurred [57]. Noncommunicable diseases now
account for almost half of all disability-adjusted life years (DALYs) in low- and middle-income
countries [58]. Although this shift is now being realized, and resources reallocated in response,
earlier research into low-cost diagnostics for noncommunicable diseases could have helped in
the better control of this new burden. For the research community to respond with agility to
ever-shifting needs in the field, direct partnerships and assessments are necessary. We would
like to see the broader technology development community focus on creating technologies that
fit current and future needs rather than forcing ill-suited technologies onto a “hot” topic. Ideal-
ly, the R&D cycle begins after establishing a clear understanding of the needs and constraints
of the end user and other stakeholders. With the right partners in place to help identify current
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problems—perhaps using a metric like DALYs directly to influence the funding of research
and development programs—it will be easier to convince peers and funders that the research
and technology development is worthwhile.
Flow of Information: Education of Stakeholders, Open Access, and
Intellectual Property
Educating stakeholders. To realize the full benefits of POC diagnostics, it will be critical
to stimulate lasting demand and use by health care workers. Even more important to the suc-
cessful adoption of POC diagnostics is the need for tests to be as good as, or more reliable than,
existing POC tests or tests for diseases that exist only as laboratory tests and do not yet exist as
POC tests, and an assurance of continuous quality control processes [59,60]. Previous launches
of less-than-successful RDTs demonstrated the need to educate health care workers in proper
test usage and inform both health care workers and community members of test reliability and
the potential for better clinical outcomes from testing [61,62]. If this information is not made
available, the acceptance and utility of these tests can be reduced significantly. End user adop-
tion is critical to success.
Open access. Significant disagreement arose surrounding the concept of open access and
intellectual property. Currently, there are two strong models emerging for the development of
technologies for use in resource-limited settings. One is the open access, do-it-yourself (DIY),
or maker movement. This group advocates for complete open access for protocols, designs,
and intellectual property so that innovators in the developing world can capitalize freely on
knowledge and resources they might not otherwise be able to access. The other group endorses
working through for-profit or nonprofit entities that seek sustainable solutions through the en-
terprise system [63]. The second group maintains that sustainability and scalability can only be
achieved by building a business. The first approach reduces the barrier to entry and democra-
tizes science; this approach, however, limits incentives for current market systems to invest in
the translation of technologies into marketable products. It also overlooks the financial chal-
lenges associated with the development of manufacturing capabilities and the development of
distribution streams. Strengths of the second approach include sustainability and a higher qual-
ity product with built-in assurances and controls; a disadvantage is slower access to products
and the potential for the concentration of knowledge in wealthier countries.
Intellectual property. The second approach also includes challenges associated with IP.
North American and European academic systems often require that the academic inventors as-
sign ownership of any IP to their academic institution. There are significant costs associated
with initiating and completing the patenting process for any new IP. Many universities are un-
willing to finance these costs unless a credible opportunity to recover them exists. To realize
better returns on their IP portfolios, Western academic institutions are not motivated to defend
patents that are not likely to result in high-volume or high-margin products. Thus, this IP
often remains unprotected, greatly limiting the ability of the inventor to generate outside funds
to commercially develop the technology for wider use. Often, such technologies are demon-
strated in pilot projects and then stall due to lack of defendable IP, which further contributes to
gaps in the value chain that result in fewer innovations in the marketplace. It may be possible,
however, to make this unprotected IP broadly available for uses that may inspire future innova-
tions. Funding mechanisms such as the Bill and Melinda Gates Foundation stipulate that IP
emerging from R&D supported by their grants be made available to developing countries at a
reasonable cost.
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Barriers in Funding of Collaborations
Many attendees stressed that collaborations between African and Western partners need to
happen very early along the value chain, even before the prototyping and design process of new
assays. The identification and demonstration of clinical and market needs were frequently stat-
ed as the most valuable aspects of these collaborations. Additionally, these relationships enable
participants to articulate specific limitations in settings that must be overcome (e.g., cultural or
region-specific technological barriers). Another discussion point centered on the lack of inno-
vation infrastructure in many East African countries, which makes it difficult for African in-
ventors to find funding to pursue new research ideas. East African scientists stressed that
collaboration within their own institutions across disciplines (e.g., between engineering and bi-
ology) remained difficult due to a lack of communication, rendering intercontinental collabo-
rations all but impossible.
A key outcome of the workshop was the identification of a need for grant mechanisms that
support initial pilot testing in Africa with African partners. It was noted that many research
funding bodies in developed countries do not allow the provision of resources for foreign inves-
tigators to be paid fairly for their participation in research projects. For instance, a foreign sci-
entist managing a pilot study of a United States-made device in Africa can often be paid as a
consultant. African scientists indicated that it would be preferable to be recognized as a coprin-
cipal investigator and compensated accordingly.
Biomedical Testing in Low Resource Settings
There is, unfortunately, a long history of Western-based organizations conducting biomedical
testing in low-resource settings to skirt regulatory or ethical requirements. A North American
or European scientist seeking to test a new technology in Africa should be mindful of this histo-
ry. Collaborations must use the highest ethical standards to establish research studies. Partner-
ships realize a greater potential when partners in low-resource settings are viewed as cocreators
rather than sources or end users of studies or technologies [64].
Proposals to Overcome Identified Barriers
After identifying what we consider to be the current main barriers in POC diagnostics, we
came to a consensus on several proposed solutions. These proposals do not represent a com-
prehensive list, but we anticipate that they will function as a starting point for action.
New Funding Mechanisms
Many of the proposed solutions were related to funding. The level of funding is secondary to
the ability of funding mechanisms to work across national and scientific borders. One sugges-
tion is the creation of more calls for proposals that emphasize the participation of multidisci-
plinary researchers and crosscutting research: for example, grants that focus on translating
technologies from the research laboratory to the clinic or grants to study areas like quality con-
trol and assurance, which are often orphans in the current funding landscape. The Center for
Affordable Medical Technologies’ Innovation Award [65] is an example of what such RFPs
might look like.
Scientists and technology developers should become educated in policies and active advo-
cates for changes in global funding paradigms. The negotiations over a proposed Global R&D
Treaty at WHO went largely unknown to the scientific communities that would benefit most
from such a proposed agreement [66,67]. The scientific community could provide a powerful
voice to the debates shaping global research funding; currently, this debate only occurs among
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policy makers and trade representatives. Innovative funding incentives can bring attention to
technologies for neglected and rare diseases.
Also proposed was the establishment of funds for national and international exchange pro-
grams for scientists, student researchers, and clinicians. It is immensely useful for biomedical
engineers to visit field sites to see processes and challenges in delivering care firsthand. Increas-
ing the numbers of interactions between clinicians and engineers can serve to educate clinicians
about what is possible now and what may be possible in the future with ongoing research
and collaboration.
Improved Timing of Collaborations across Borders
There was a strong incentive among workshop attendees to work together and collaborate;
however, participants acknowledged the critical disconnects in communication and funding.
Without ongoing communication mechanisms—such as through conferences, literature, and
real time collaborations—a practical disconnect will remain between the perceived needs of de-
velopers and end users. These mismatches will continue to grow in the absence
of collaborations.
It was also noted that developers of technologies and POC diagnostics should clearly com-
municate timelines to potential end users. When this timeline—for the development pipeline
and for product launch—is not clear, end users often grow wary of hearing about “the next
new thing” that is promised to save lives but never arrives. When obstacles in the value chain
are acknowledged before product development, some of these misperceptions can be avoided.
Western scientists may be rewarded by granting mechanisms for overly optimistic projections
of success in terms of time and impact. There are real disadvantages in terms of buy-in from
African partners when these projections are unmet. It is the responsibility of technology devel-
opers to be pragmatic and set realistic expectations.
There are several ways for funders, governments, and policy makers to promote active col-
laborations between individuals and institutions. First, they can facilitate contact between
groups. It is often difficult for technology developers and clinical practitioners to find collabo-
rative partners with mutual interests and complementary skills. Our workshop provided a
venue for such connections to begin to percolate; however, only with repeated interactions that
build familiarity and trust between participants can strong and mutually-supportive collabora-
tions be forged from trust and familiarity. Support for other international conferences is one
way to foster new partnerships. Other mechanisms include using social media and the Internet
to connect people with similar interests and complementary skill sets. Establishment of a virtu-
al community of technology developers, scientists, and clinicians similar to the Global Health
Delivery Online (www.ghdonline.org) community could provide a secure forum for the active
exchange of ideas for those without the resources for travel. GHDonline is a free, subscription-
based website that requires users to log into a social media environment. This semiprivate,
moderated forum has been very useful to clinicians all over the world. We believe that new col-
laborations could nucleate from such an environment. A moderated online forum could also
serve as a venue for the training, technology assessment, and dissemination of results. Modera-
tion requires funding; we feel that an unmoderated site would be unsuccessful. Second, the es-
tablishment of proper protocols for research is confusing and difficult to navigate when
scientific teams consist of individuals from different countries. Funding agencies could support
and promote country specific mentoring services to shepherd investigators through the pro-
cess. Stakeholders in technology development and in patient care could greatly benefit from
such mentoring.
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Education of Stakeholders
There are often barriers to the clinical adoption of POC tests due to the lack of information or
misinformation about the tests. Users will not transition to a new test simply because it is
touted as better than the standard of care; they must be convinced with data and trained by
knowledgeable users. In the best case, these knowledgeable users are their peers. Trust between
trainers and technology-adopters is paramount when patient outcomes are at stake. The fol-
lowing mechanisms have the potential to mainstream simple tests into routine medical prac-
tice: (i) develop and update health curricula to reflect advances in POC diagnostics; (ii) provide
refresher workshops to educate health care workers on developments in POC diagnostics; (iii)
disseminate updates of information or progress using mass media; (iv) establish dedicated on-
line resources for the use and interpretation of POC diagnostics.
Barriers can also arise from misunderstandings. In some cases, there is a misperception that
POC tests will completely replace clinical laboratories and extract jobs and financial support
from hospitals. POC tests will ideally augment medical systems found within clinical laborato-
ries rather than to replace clinical laboratories altogether. Working with clinical laboratories
during development and communicating objectives can avoid misunderstandings from becom-
ing obstacles. The challenges associated with distributing POC tests to end users can drive the
development of business models that create new jobs, such as health care workers that buy the
tests, transport them to test sites, and perform the assays.
Another important avenue for education is the scientific literature. New technologies and
discoveries are often published behind prohibitively expensive paywalls that prevent end users
in both developed and developing countries from accessing valuable knowledge about effec-
tiveness and validation. Open-access publishing (e.g., the Public Library of Science) and open
access archives (e.g., ArXiv and bioRxiv) provide two alternatives that can reduce barriers to
access and enable the education of stakeholders. Open access to high quality scientific literature
will ultimately promote the adoption of the best technologies available to solve
appropriate problems.
Re-evaluation of the Current Paradigms in POC Technology Promotion
When the Bill and Melinda Gates Foundation and other agencies set forth a list of priorities for
POC testing in low-resource settings approximately one decade ago, a number of assumptions
were made regarding the forward progress of the field. We feel that a reexamination of those
assumptions is warranted in the context of what has been learned in the past ten years. For ex-
ample, one of the original papers suggests: “. . . when a new test is introduced, it will initially be
available to the providers with the most sophisticated infrastructure, followed by those with
progressively worse infrastructure” [68]. It is unclear whether such an implementation model
has been successful.
Further, the cost of a POC test—including necessary labor, transportation, storage, and
quality control—in many cases must be very low to offer a true advantage. In some cases, the
decrease in cost and increase in functionality of associated technologies, like mobile devices,
may shift the balance back toward a model that approximates the function of a centralized lab-
oratory. A model consisting of regional centers with testing equipment can be more expensive
and have a slower turn-around time than centralized testing performed at a single national cen-
ter but combined with mobile reporting systems.
The assumption that the lowest cost test will be the best test for low resource settings was
challenged at the workshop. Many participants noted pushback from clinicians and patients
when an inexpensive test was perceived as shoddy or substandard. The presence of one poorly
executed test in the marketplace can negatively impact end user perceptions of POC tests.
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Quality control and test validation has emerged as an area of increased concern over the last
decade. It has been well documented that pharmaceuticals are substandard or counterfeited at
alarming rates in both low- and high-resource settings [69]. It is a lesser-acknowledged prob-
lem that POC diagnostics are also subject to poor regulatory oversight and counterfeiting activ-
ity [70]. When quality control is poor and tests do not result in better patient care, those tests
will be rejected by patients and clinicians. The group identified a need for POC diagnostics
with built-in quality control and quality assurance measures. Incorporating appropriate inno-
vations, such as temperature-monitoring labels, serializing tests, mobile phone–based product
verification, and tracking expiration dates were described. Mechanisms for postmarket surveil-
lance are challenging in many settings, but this need should be addressed by both manufactur-
ers and regulatory agencies.
Promotion of African Research Laboratories
We believe that strengthening the ability of laboratories in low-resource settings to perform in-
novative research in the area of POC diagnostics is an investment that could have the most
transformative impact on the field. African scientists are uniquely positioned to address all of
the links along the local value chain. There are several nascent groups with the potential to gal-
vanize the scientific community interested in diagnostics development in Africa. Examples in-
clude the African Society for Laboratory Medicine (www.aslm.org) and African Network for
Drugs and Diagnostics Innovation (http://www.andi-africa.org). Analogies were drawn to the
recent surge in innovation surrounding mobile technologies in Africa. The “Silicon Savannah”
concept has largely been applied to information technologies and not to biomedicine [71].
These organizations should aim to continue to promote and strengthen the concept of African
innovation in translational biomedicine.
It was also noted that public universities in Africa do not yet have the same culture of inter-
disciplinary research as in the Western world. Efforts to promote research that crosses over tra-
ditional academic “silos” is necessary to generate crossdisciplinary research and realize new
POC technologies. Funding agencies and governments can have an impact on this kind of col-
laboration within African institutions. Many North American and European universities have
adopted more crosscutting research models in the biological sciences. The transition has taken
years, due to the lack of clear rewards for participating in collaborative research (as opposed to
working alone). In the US, the National Institutes of Health has focused on translational re-
search through the creation of a new center in 2011 [72], and several private funders have an-
nounced requests for proposals that require a collaborative approach. These changes, and
others, have begun to drive research in more multidisciplinary directions. Strengthening of the
regulatory infrastructure in African countries was cited as another investment that could great-
ly change the impact of African innovation. Clear mechanisms for getting legal approval and
for postmarket surveillance are needed if devices are to make it to market quickly and patient
safety is to be maintained.
Sustainability
Overarching all of these recommendations is the need for sustainability. It is not enough to
bring a new test to the marketplace and have it be adopted. Supply chains must be maintained,
procurement must be simplified, and repairs or changes in protocols must be easy to commu-
nicate to the end user. All of these components require systems-level thinking on the part of
the technology developers and distributors. Practical issues of sustainability should be dis-
cussed early and revisited often. Further, the value of POC diagnostics to overall health care
must be made clear to funders and governments in quantitative terms. Use of POC diagnostics
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should be included in epidemiological and economic modeling studies in order to attach a
value to the assay or the technology. When the use of a POC diagnostic improves health care
outcomes and reduces the time to initiate as well as the cost of treatment, it becomes easier to
lobby for the allocation of future expenditures to be directed towards the deployment of specif-
ic POC diagnostics.
Several attendees suggested the establishment of mechanisms for the sustainable production
of the solution (i.e., the POC diagnostic) in the country or region of use. These mechanisms in-
clude protocols for transferring technologies from a developed country to a developing coun-
try. Also important is the stimulation of market forces to drive the development and
implementation of these new technologies. Sustainability depends on building capacity in Af-
rica for interdisciplinary training and research. Ideally, technologies will arise within Africa
and remove the current challenges associated with the transfer of technology between devel-
oped and developing countries. Student and scientist exchanges will also support sustainability
by enabling African scientists to gain technical skills and interdisciplinary training and teach-
ing North American and European scientists how to innovate in low-resource settings and to
assess specific needs.
Summary
Amajor goal of the 1st International Point-of-Care Diagnostic Workshop in Nairobi, Kenya
was to provide a forum for open dialog concerning current challenges in, and potential solu-
tions for, the development of the next generation of POC diagnostics. The focus was not solely
on descriptions of new technologies in development but also included demonstrations of their
use in a field setting. The resulting conversations identified a number of obstacles to the suc-
cessful translation of prototypes into field-deployable tools. These obstacles superseded those
typically encountered in research; changes must be implemented at the institutional and gov-
ernmental level to enable equitable collaborations between Western and African partners, and
proper funding mechanisms must be established to support these collaborations. Additionally,
this workshop showcased emerging technologies for POC tests and fostered new partnerships
between technology developers and African research laboratories. Equitable partnerships are
critical for the successful implementation of new POC technology. The attendees agreed that
the most effective methods to effect change require improved communication of needs, ideas
and abilities, and a conduit for the sharing of experiences and information. We plan to imple-
ment many of the changes that are suggested here in our own research programs and to use fu-
ture conferences and workshops to guide the development of both technologies and
partnerships. Our successes and failures will serve as models for those scientists striving to de-
velop technological and biomedical solutions to similar problems in global health.
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